Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3723468 | 0.78 | MEN1 (0.39) | SMN1; SMN2ALDH1A1L3MBTL1KMT2AMAPT | |
| SCHEMBL9153248 | 0.77 | MEN1 (0.38) | SMN1; SMN2ALDH1A1L3MBTL1KMT2AMAPT | |
| SCHEMBL20230776 | 0.77 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL31255109 | 0.77 | MEN1 (0.38) | SMN1; SMN2ALDH1A1KMT2AKDM4EMEN1 | |
| SCHEMBL6181403 | 0.77 | RPS6KA5 (0.34) | SMN1; SMN2ALDH1A1L3MBTL1KMT2ARPS6KA5 | |
| SCHEMBL31254843 | 0.76 | SMN1; SMN2 (0.30) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL13012807 | 0.75 | — | — | |
| SCHEMBL1416493 | 0.75 | ABL1 (0.37) | SMN1; SMN2ALDH1A1KMT2ARPS6KA5KDM4E | |
| SCHEMBL8054292 | 0.75 | CSNK1A1 (0.37) | SMN1; SMN2ALDH1A1KMT2AMAPTPIN1 | |
| SCHEMBL31254993 | 0.75 | KDM4E (0.32) | SMN1; SMN2ALDH1A1KMT2AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4685141-A1 | ISOINDOLINE DERIVATIVE, BENZOINDOLE DERIVATIVE AND USE THEREOF | Shanghai Helioson Pharmaceutical Co., Ltd. (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-12528826-B2 | [1,4]oxazepino[2,3-c]quinolinone derivatives as BCL6 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2026-01-20 | — | — | US | disclosed |
| US-12357631-B2 | Pyrrolo[2,3-B]pyridin derivatives as inhibitors of influenza virus replication | COCRYSTAL PHARMA, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| EP-3829719-B1 | PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION | COCRYSTAL PHARMA INC (US) | 2025-04-02 | — | — | EP | disclosed |
| WO-2025017305-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2025-01-23 | — | — | WO | disclosed |
| US-20240217987-A1 | INHIBITOR COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-04 | — | — | US | disclosed |
| CN-112638477-B | Pyrrolo [2,3-B ] pyridine derivatives as inhibitors of influenza virus replication | 共晶制药公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-116547281-A | Isoxazolidines as RIPK1 inhibitors and uses thereof | 赛诺菲 | 2023-08-04 | — | — | CN | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
| EP-4157835-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-04-05 | — | — | EP | disclosed |
| WO-2012083117-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-21 | — | — | WO | disclosed |
| EP-2442809-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Incorporated (US) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010148197-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010148197-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-23 | — | — | WO | disclosed |
| CN-1068327-C | 2,7-substituierte octahydro-1H-pyrido [1,2-A] pyrazin derivate | PFIZER (US) | 2001-07-11 | — | — | CN | disclosed |
| CN-1168672-A | 2,7-substituierte octahydro-1H-pyrido [1,2-A] pyrazin derivate | PFIZER (US) | 1997-12-24 | — | — | CN | disclosed |
| US-4994460-A | Treatment or prevention of disorders resulting from central nervous system anoxia | BRISTOL-MYERS SQUIBB CO. (US) | 1991-02-19 | — | — | US | disclosed |
| EP-0400661-A1 | Agents for treatment of brain ischemia | Bristol-Myers Squibb Company (US) | 1990-12-05 | — | — | EP | disclosed |
| US-4605655-A | NEUROLEPTIC AGENTS; NO MOVEMENT DISORDER SIDE EFFECTS | BRISTOL-MYERS COMPANY (US) | 1986-08-12 | — | — | US | disclosed |
| US-4423049-A | TRANQUILIZERS | MEAD JOHNSON & COMPANY (US) | 1983-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528826-B2 | [1,4]oxazepino[2,3-c]quinolinone derivatives as BCL6 inhibitors | BCL6, BCL6B, BCL3 | SMN1; SMN2 3568/4885ALDH1A1 1668/4885L3MBTL1 1004/4885 |
| US-20240217987-A1 | INHIBITOR COMPOUNDS | BCL6, BCL6B, BCL3 | SMN1; SMN2 4441/4885ALDH1A1 2960/4885L3MBTL1 653/4885 |
| US-12357631-B2 | Pyrrolo[2,3-B]pyridin derivatives as inhibitors of influenza virus replication | PIR, PNPO, IDO1 | SMN1; SMN2 4681/4885ALDH1A1 2943/4885L3MBTL1 3998/4885 |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | SMN1; SMN2 4753/4885ALDH1A1 2211/4885L3MBTL1 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.